



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

1134/03/07/2019/WG/H&V

Warszawa, 3 lipca 2019 r.

Szanowny Pan

dr n. med. Roman Topór- Mądry

Prezes Agencji Oceny Technologii

Medycznych i Taryfikacji

ul. Przeskok 2

00-032 Warszawa

Dotyczy:

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury
02-092 Warszawa (Polska)

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]						[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury
02-092 Warszawa (Polska)

--	--	--	--	--



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

			[REDACTED]	
--	--	--	------------	--

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury
02-092 Warszawa (Polska)

[REDACTED]
[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury
02-092 Warszawa (Polska)

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury
02-092 Warszawa (Polska)

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury
02-092 Warszawa (Polska)

Z poważaniem,

Małgorzata Konopka-Pliszka
Dyrektor ds. Kontaktów Instytucjonalnych i Polityki Zdrowotnej

Załączniki:

- 1.1. Aktualizacja wyników – analiza ekonomiczna, analiza wpływu na budżet (pdf)
- 1.2. Aktualizacja wyników – BIA, CMA, AR (xlsm)



Pfizer Polska Sp. z o.o.

ul. Żwirki i Wigury 16B
02-092 Warszawa (Polska)

Piśmiennictwo:

- Bonovas 2017** Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. *Aliment Pharmacol Ther* 2018; 47(4):454-465
- Borman 2018** Borman ZA, Côté-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. *Expert Rev Gastroenterol Hepatol*. 2018 Nov;12(11):1101-1108.
- Coskun 2013** Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. *Pharmacol Res* 2013; 76:1-8
- Danese 2018** Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. *Inflamm Bowel Dis* 2018
- Kokkinidis 2017** Weisshof R, Golan MA, Yvellez OV, Rubin DT. The use of tofacitinib in the treatment of inflammatory bowel disease. *Immunotherapy*. 2018 Aug; 10(10):837-849.
- Panés 2019** Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W. Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy. *J Crohns Colitis*. 2019 Feb 27. pii: jjz048. doi: 10.1093/ecco-jcc/jjz048. [Epub ahead of print] PubMed PMID: 30809631.
- Paschos 2018** Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. *Annals of Gastroenterology* (2018) 31, 1-11
- Paschos 2018a** Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. *Aliment Pharmacol Ther* 2018; 48(11-12):1174-1185
- Singh 2018** Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. *Aliment Pharmacol Ther* 2018; 47(2):162-175
- Trigo-Vicente 2018** Trigo-Vicente C, Gimeno-Ballester V, Garcia-Lopez S, Lopez-Del Val A. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. *Int J Clin Pharm* 2018; 40(6):1411-1419
- Weisshof 2018** Kokkinidis DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, Texakalidis PT, Economopoulos KP, Kousoulis AA. Emerging treatments for ulcerative colitis: a systematic review. *Scand J Gastroenterol*. 2017 Sep;52(9):923-931.
- White 2018** White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. Review article: novel oral-targeted therapies in inflammatory bowel disease. *Aliment Pharmacol Ther* 2018; 47(12):1610-1622